BridgeBio Oncology Therapeutics (BBOT) vs X4 Pharmaceuticals (XFOR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
X4 Pharmaceuticals (XFOR) has outperformed BridgeBio Oncology Therapeutics (BBOT) over the past year, losing 18.3% versus a loss of 71.8%. X4 Pharmaceuticals is the larger company by market cap ($278.6 million vs $275.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BBOT | XFOR |
|---|---|---|
| Share price | $3.44 | $2.81 |
| Market cap | $275.80M | $278.60M |
| 1-day change | -1.71% | +1.44% |
| YTD return | -72.52% | -29.75% |
| 1-year return | -71.83% | -18.31% |
| 5-year return | — | -98.21% |
| P/E ratio (TTM) | — | 140.50 |
| EPS (TTM) | $-0.07 | $0.02 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $14.87 | $4.83 |
| 52-week low | $3.36 | $2.70 |
| Distance from 52-week high | -76.87% | -41.82% |
| Analyst consensus | none | none |
| Avg. price target upside | +613.66% | +312.81% |
| Average volume | 468.83K | 849.98K |
| Shares outstanding | 80.17M | 99.15M |
| Employees | 88 | 45 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- XFOR has outperformed BBOT by 53.5 percentage points over the past year.
About BridgeBio Oncology Therapeutics
BBOT stock →BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models.
Health Care · Biotechnology: Pharmaceutical Preparations · 88 employees
About X4 Pharmaceuticals
XFOR stock →X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 45 employees
BBOT vs XFOR FAQ
Which is bigger, BridgeBio Oncology Therapeutics or X4 Pharmaceuticals?
X4 Pharmaceuticals (XFOR) is larger, with a market capitalization of $278.60M compared with $275.80M for BridgeBio Oncology Therapeutics (BBOT).
Which stock has performed better over the past year, BBOT or XFOR?
XFOR returned -18.31% over the past 12 months, compared with -71.83% for BBOT (price return, excluding dividends). Past performance does not predict future results.
Are BridgeBio Oncology Therapeutics and X4 Pharmaceuticals in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for BridgeBio Oncology Therapeutics and Biotechnology: Biological Products (No Diagnostic Substances) for X4 Pharmaceuticals.